Be a part of a new era
in cellular therapy

for the potential treatment of human papillomavirus (HPV) 16-associated cancers, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer).

Many advancements have been made in the treatment of cancer, including a recent focus to develop treatments that activate the immune system to fight cancer, called immunotherapies.

Despite this progress, existing immunotherapies are effective in a relatively small number of patients with HPV 16-associated cancers. Furthermore, in some cases even when therapies are initially effective, the disease eventually no longer responds to treatment and progresses.

Rubius Therapeutics® is developing an investigational cellular therapy, called RTX-321, that is engineered to selectively target HPV 16-associated cancers and potentially induce an immune response against the cancer, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer).

About RTX-321
RTX-321 is an investigational cellular therapy that aims to selectively target HPV 16-associated cancers and potentially induce an immune response against the cancer.

RTX-321 is an investigational cellular therapy that is being evaluated in a Phase 1 clinical trial for the treatment of patients with HPV 16-associated cancers, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer). RTX-321 is engineered to express cancer-fighting molecules and specific proteins, known as antigens, on the cell’s surface. These antigens that are bound to the cell surface may selectively instruct only the cells of the immune system with the ability to potentially recognize and attack the tumor.

Learn more about the RTX-321 Clinical Trial

RTX‑321 Phase 1 Clinical Trial

Complete a patient screener to see if you may be able to participate.

Patient Screener

Patient Screener

Sign up to learn more about Red Cell Therapeutics™ and cancer clinical trials.

Sign Up Form

Sign Up Form

Rubius Therapeutics is now enrolling patients in a phase 1 clinical trial of RTX-321 for the treatment of patients with HPV 16-associated cancers.

Complete a patient screener to see if you may be able to participate.

Complete a patient screener to see if you may be able to participate.

Thank you! You may be a potential candidate for a study doctor to evaluate for participation in this study.

If you wish to be connected to a clinical trial site in the RTX-321 study, please fill in your contact information below. Someone from our Patient Advocacy Team may reach out to you to determine your interest and if you would meet the requirements to be evaluated by a study doctor for screening in the RTX-321 study. Your personal information, including information entered below and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.

NEXT

Thank you!

Based on the information provided, you may not meet the requirements for this study. We want to thank you for your interest – patient volunteers and their family members are an essential part of the development of new therapies for cancer. If you still would like to learn more about Red Cell Therapeutics™ and receive updates about clinical trials that might be available in your area for the potential treatment of cancer for yourself or a loved one, sign up here.

Thank you for your submission.

Someone from our Patient Advocacy Team may reach out to you to determine your interest and if you would meet the requirements to be evaluated by a study doctor for screening in the RTX-321 study. Your personal information, including information entered previously and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.